Evidence map›Paper›PMID 32102137›Full record

SynthesisZhongguo fei ai za zhi = Chinese journal of lung cancer2020

[Research Progress in Consistency of Driver Gene Status between Primary and Corresponding Metastatic Lesions in Non-small Cell Lung Cancer].

Bing Zhou, Jianping Xiong

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bing ZhouDepartment of Pathology, The Affiliated Jiujiang Hospital of Nanchang University, Jiujiang 332000, China.
Jianping XiongDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Jiujiang University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC), as the most common pathological type of lung cancer, has the characteristics of high malignancy and aggressiveness, and the lymph nodes and different organ metastases are prone to occur in advanced stages. In recent years, with the development of precision medicine, drug resistance and treatment failure in NSCLC metastasis sites have brought difficulties for molecular targeted therapy. And studies have confirmed that these may be related to new molecular changes after tumor metastasis. This review is to describe the state of the driving genes in the primary and metastatic sites of NSCLC, and systematically review the research progress on the consistency of the state of the driving genes between the primary and corresponding metastatic lesions, which provides a new idea for exploring the molecular targeted therapy of metastatic NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungHumansLung NeoplasmsLymphatic MetastasisMolecular Targeted TherapyDriver geneLung neoplasmsMetastatic lesionsPrimary lesions

Identifiers

PMID32102137
PMCPMC7118335
OpenAlexW3010016133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.